Cromos Pharma, where the patients are

R&D Trends

Harlan Contract Research Services, Bertin Pharma collaborate

Wednesday, March 5, 2014 01:03 PM

Harlan Contract Research Services (CRS), a privately held provider of general and specialty toxicology services, and Bertin Pharma, a global solution provider offering R&D outsourcing services headquartered in France, have announced a strategic partnership for early drug development. The companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies.

More... »

CRF Health eCOA webinar series

Perrigo, Transition Therapeutics modify rights of ELND005 program

Monday, March 3, 2014 12:52 PM

Transition Therapeutics has acquired an Irish domiciled company, the holder of all development and commercialization rights of neuropsychiatric drug candidate ELND005, which will become a subsidiary of Transition. Transition also announced a $15 million investment by Perrigo to acquire approximately 7% of Transition's common shares.

More... »


Abide Therapeutics, Celgene collaborate on immune disorders

Monday, March 3, 2014 12:50 PM

Abide Therapeutics has entered into a strategic collaboration with Celgeneto discover and develop new drugs in inflammation and immunology. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology.

More... »

Roche, Discuva collaborate on new antibiotics

Monday, March 3, 2014 12:47 PM

Roche and Discuva have entered into a worldwide collaboration and license agreement for the discovery and development of new antibiotics to treat life-threatening infections caused by multi-drug resistant Gram-negative bacteria using Discuva’s proprietary SATINtechnology platform.

More... »

NIH adds genetic health information to online database

Friday, February 28, 2014 12:07 PM

Researchers now will have access to genetic data linked to medical information on a diverse group of more than 78,000 people, enabling investigations into many diseases and conditions.

More... »

Report: pharmacovigilance market, service providers to reach $5B globally in 2019

Friday, February 28, 2014 12:02 PM

According to a new market report published by Transparency Market Research, the global pharmacovigilance market was valued at $2,147.3 million in 2012 and is estimated to reach a market worth $5,008.2 million in 2019, at a CAGR of 12.9% from 2013 to 2019.

More... »

RedHill Biopharma, Salix Pharmaceuticals ink license agreement

Friday, February 28, 2014 12:00 PM

Salix Pharmaceuticals, a North Carolina-based developer and marketer of prescription pharmaceutical products and medical devices, and RedHill Biopharma, an emerging Israeli biopharmaceutical company, have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.

More... »

Dystonia Europe, EPDA partner with Boston Scientific

Wednesday, February 26, 2014 01:05 PM

Dystonia Europe (DE) and the European Parkinson's Disease Association (EPDA) are collaborating with Boston Scientific, a global medical technology provider. The aim of these partnerships is to increase awareness, understanding of solutions and to take initiatives in the world wide fight against Parkinson's disease and dystonia, two areas of high unmet need.

More... »

Ardelyx licenses phosphate inhibitor program to Sanofi in $198M deal

Wednesday, February 26, 2014 01:03 PM

Ardelyx, a venture-funded biopharmaceutical company, has licensed to Sanofi its novel phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2). Ardelyx will receive an undisclosed upfront payment from Sanofi. Total development and regulatory milestones could potentially reach up to $198 million. Ardelyx also would be entitled to royalties on product sales. In addition, Ardelyx retains an option to participate in co-promotional activities for the U.S. market.

More... »

DOD selects Bavarian Nordic's vaccine platform for new vaccine development

Wednesday, February 26, 2014 01:00 PM

Bavarian Nordic’s MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the U.S. Department of Defense, for development of a vaccine against two potential biological threats to national security—Burkholderia pseudomallei and Burkholderia mallei. Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs